These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Plasminogen activator inhibitor-1 4G/5G and the MTHFR 677C/T polymorphisms and susceptibility to polycystic ovary syndrome: a meta-analysis. Lee YH; Song GG Eur J Obstet Gynecol Reprod Biol; 2014 Apr; 175():8-14. PubMed ID: 24439532 [TBL] [Abstract][Full Text] [Related]
3. Plasminogen activator inhibitor 1 and methylenetetrahydrofolate reductase gene mutations in iranian women with polycystic ovary syndrome. Idali F; Zareii S; Mohammad-Zadeh A; Reihany-Sabet F; Akbarzadeh-Pasha Z; Khorram-Khorshid HR; Zarnani AH; Jeddi-Tehrani M Am J Reprod Immunol; 2012 Nov; 68(5):400-7. PubMed ID: 22882325 [TBL] [Abstract][Full Text] [Related]
4. [Association of genetic polymorphisms in plasminogen activator inhibitor-1 gene and 5,10-methylenetetrahydrofolate reductase gene with recurrent early spontaneous abortion]. Guan LX; Du XY; Wang JX; Gao L; Wang RL; Li HB; Wang SX Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Jun; 22(3):330-3. PubMed ID: 15952129 [TBL] [Abstract][Full Text] [Related]
5. MTHFR C 677T mutation and 4G/5G PAI-1 polymorphism in patient with polycystic ovarian syndrome. Radaković B; Goldstajn MS Coll Antropol; 2007 Sep; 31(3):919-21. PubMed ID: 18041407 [TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome. Glueck CJ; Sieve L; Zhu B; Wang P Metabolism; 2006 Mar; 55(3):345-52. PubMed ID: 16483878 [TBL] [Abstract][Full Text] [Related]
7. [Correlation between 4G and 5G genetypes distribution of plasminogen activator inhibitor-1 gene polymorphism in its promoter region with polycystic ovarian syndrome]. Zhao JL; Chen ZJ; Zhao YR; Zhao LX; Wang LC; Tang R; Ma ZX Zhonghua Fu Chan Ke Za Zhi; 2005 Aug; 40(8):528-31. PubMed ID: 16202290 [TBL] [Abstract][Full Text] [Related]
8. 4G/5G polymorphism of PAI-1 gene and Alu-repeat I/D polymorphism of TPA gene in Turkish patients with polycystic ovary syndrome. Karadeniz M; Erdogan M; Berdeli A; Saygili F; Yilmaz C J Assist Reprod Genet; 2007 Sep; 24(9):412-8. PubMed ID: 17661167 [TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor-1, factor V, factor II and methylenetetrahydrofolate reductase polymorphisms in women with recurrent miscarriage. Pietropolli A; Giuliani E; Bruno V; Patrizi L; Piccione E; Ticconi C J Obstet Gynaecol; 2014 Apr; 34(3):229-34. PubMed ID: 24484533 [TBL] [Abstract][Full Text] [Related]
10. Association of methylenetetrahydrofolate reductase gene C677T polymorphism with polycystic ovary syndrome risk: a systematic review and meta-analysis update. Fu LY; Dai LM; Li XG; Zhang K; Bai Y Eur J Obstet Gynecol Reprod Biol; 2014 Jan; 172():56-61. PubMed ID: 24192663 [TBL] [Abstract][Full Text] [Related]
11. Association between a single nucleotide polymorphism in MTHFR gene and polycystic ovary syndrome. Choi SW; Gu BH; Ramakrishna S; Park JM; Baek KH Eur J Obstet Gynecol Reprod Biol; 2009 Jul; 145(1):85-8. PubMed ID: 19427093 [TBL] [Abstract][Full Text] [Related]
12. The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Diamanti-Kandarakis E; Palioniko G; Alexandraki K; Bergiele A; Koutsouba T; Bartzis M Eur J Endocrinol; 2004 Jun; 150(6):793-8. PubMed ID: 15191349 [TBL] [Abstract][Full Text] [Related]
13. [Association of methylenetetrahydrofolate reductase gene polymorphisms with polycystic ovary syndrome]. Qi Q; Zhang H; Yu M; Wang X; Wang Z; Xu L; Wang J; Mu H Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Jun; 32(3):400-4. PubMed ID: 26037361 [TBL] [Abstract][Full Text] [Related]
14. The plasminogen activator inhibitor-1 (PAI-1) gene -844 A/G and -675 4G/5G promoter polymorphism significantly influences plasma PAI-1 levels in women with polycystic ovary syndrome. Lin S; Huiya Z; Bo L; Wei W; Yongmei G Endocrine; 2009 Dec; 36(3):503-9. PubMed ID: 19856137 [TBL] [Abstract][Full Text] [Related]
15. Gender-specific association of the plasminogen activator inhibitor-1 4G/5G polymorphism with central arterial blood pressure. Björck HM; Eriksson P; Alehagen U; De Basso R; Ljungberg LU; Persson K; Dahlström U; Länne T Am J Hypertens; 2011 Jul; 24(7):802-8. PubMed ID: 21490692 [TBL] [Abstract][Full Text] [Related]
16. [Plasminogen activator inhibitor type 1 activity in women with unexplained very early recurrent pregnancy loss]. Ivanov P; Komsa-Penkova R; Ivanov I; Konova E; Kovacheva K; Simeonova M; Tanchev S Akush Ginekol (Sofiia); 2010; 49(5):3-8. PubMed ID: 21268395 [TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history. Jorgenson E; Deitcher SR; Cicek M; Liu X; Plummer S; Casey G; Witte JS Prostate; 2007 Feb; 67(2):172-7. PubMed ID: 17044080 [TBL] [Abstract][Full Text] [Related]
19. [Reproductive problems in women with PCOS, the impact of PAL-1 CARRIERS OF 4G PAI -1 polymorphism and BMI]. Komsa-Penkova R; Golemanov G; Georgieva G; Slavov N; Popovski K; Ivanov P; Kovacheva K; Atanasova M; Blajev A Akush Ginekol (Sofiia); 2014; 53(5):3-9. PubMed ID: 25558663 [TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator inhibitor I 4G/5G polymorphism in neonatal respiratory distress syndrome. Armangil D; Yurdakök M; Okur H; Gürgey A Clin Appl Thromb Hemost; 2011 Aug; 17(4):352-7. PubMed ID: 20460339 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]